Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma.
• While initial treatment response rates are high, disease resistance and transformation to aggressive lymphoma present significant challenges.
• Current treatment strategies require refinement to align with evolving understanding of FL biology and patient-specific disease progression.

Purpose of the Study:

• To summarize key discussions from the Lymphoma Research Foundation's 2024 Follicular Lymphoma Scientific Workshop.
• To highlight updates in FL biology, first-line treatment strategies, and the clinical significance of early progression (POD24).
• To explore novel endpoints in clinical trials and the potential for redefining cure in FL.

Main Methods:

• Expert consensus and discussion during a biannual scientific workshop.
• Review of current clinical data and emerging therapeutic agents.
• Focus on challenges in treatment sequencing and aligning therapies with tumor biology.

Main Results:

• Novel agents show encouraging early clinical data for FL treatment.
• Progression of disease within 24 months (POD24) is a critical factor impacting treatment sequencing and outcomes.
• Advances in understanding FL biology and the tumor microenvironment are crucial for developing new therapies.

Conclusions:

• Aligning treatment with tumor biology and optimizing therapy sequencing are key challenges in managing FL.
• The development of novel agents and refined clinical trial designs are essential for improving patient outcomes.
• Redefining cure in FL necessitates a comprehensive approach integrating biology, treatment sequencing, and patient-specific factors.